Neuroprotective effects of zonisamide target astrocyte

Annals of Neurology

Volumn 67, Issue 2, 2010, Pages 239-249

  Asanuma, Masato ^a   Miyazaki, Ikuko ^a   Diaz Corrales, Francisco J ^a,c   Kimoto, Naotaka ^a   Kikkawa, Yuri ^a   Takeshima, Mika ^a   Miyoshi, Ko ^a   Murata, Miho ^b  

^a OKAYAMA UNIVERSITY   (Japan)

^b National Center Hospital of Neurology and Psychiatry   (Japan)

^c CABIMER Andalusian Center for Molecular Biology and Regenerative Medicine CSIC University of Seville UPO   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CARBIDOPA PLUS LEVODOPA; CYSTINE; GLUTAMIC ACID; GLUTATHIONE; OXIDOPAMINE; PROTEIN S100B; ZONISAMIDE;

AMINO ACID TRANSPORT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASTROCYTE; BASAL GANGLION; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC NERVE CELL; DRUG DOSE COMPARISON; DRUG MECHANISM; DRUG TARGETING; GLUTATHIONE METABOLISM; MACROGLIA; MALE; MOUSE; NERVE DEGENERATION; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PARKINSONISM; PRIORITY JOURNAL;

ANIMALS; ANTIPARKINSON AGENTS; ASTROCYTES; BASAL GANGLIA; CARBIDOPA; CELLS, CULTURED; DISEASE MODELS, ANIMAL; DOPAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; GLIAL FIBRILLARY ACIDIC PROTEIN; GLUTATHIONE; ISOXAZOLES; MALE; MICE; MICE, INBRED ICR; NERVE GROWTH FACTORS; NEUROPROTECTIVE AGENTS; OXIDOPAMINE; PARKINSON DISEASE; S100 PROTEINS; TYROSINE 3-MONOOXYGENASE;

EID: 77949380692     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.21885     Document Type: Article

References (43)

1. Murata M, Horiuchi E, Kanazawa I. Zonisamide has beneficial effects on Parkinson's disease patients. Neurosci Res 2001;41: 397-399.
2. Murata M. Novel therapeutic effects of the anti-convulsant, zonisamide, on Parkinson's disease. Curr Pharm Des 2004;10: 687-693.
3. Murata M, Hasegawa K, Kanazawa I, et al. Zonisamide improves motor function in Parkinson disease: a randomized, double-blind study. Neurology 2007;68:45-50.
4. Kito M, Maehara M, Watanabe K. Mechanisms of T-type calcium channel blockade by zonisamide. Seizure 1996;5:115-119.
5. Suzuki S, Kawakami K, Nishimura S, et al. Zonisamide blocks T-type calcium channel in cultured neurons of rat cerebral cortex. Epilepsy Res 1992;12:21-27.
6. Okada M, Kaneko S, Hirano T, et al. Effects of zonisamide on extracellular levels of monoamine and its metabolite, and on Ca2+ dependent dopamine release. Epilepsy Res 1992;13: 113-119.
7. Okada M, Kaneko S, Hirano T, et al. Effects of zonisamide on dopaminergic system. Epilepsy Res 1995;22:193-205.
8. Gluck MR, Santana LA, Granson H, Yahr MD. Novel dopamine releasing response of an anti-convulsant agent with possible anti-Parkinson's activity. J Neural Transm 2004;111:713-724.
9. Ichikawa J, Dai J, Meltzer HY. Lithium differs from anticonvulsant mood stabilizers in prefrontal cortical and accumbal dopamine release: role of 5-HT1A receptor agonism. Brain Res 2005;1049: 182-190.
10. Shih AY, Erb H, Sun X, et al. Cystine/glutamate exchange modulates glutathione supply for neuroprotection from oxidative stress and cell proliferation. J Neurosci 2006;26:10514-10523.
11. Wang XF, Cynader MS. Astrocytes provide cysteine to neurons by releasing glutathione. J Neurochem 2000;74:1434-1442.
12. Chinta SJ, Andersen JK. Reversible inhibition of mitochondrial complex I activity following chronic dopaminergic glutathione depletion in vitro: implications for Parkinson's disease. Free Radic Biol Med 2006;41:1442-1448.
13. Chinta SJ, Kumar MJ, Hsu M, et al. Inducible alterations of glutathione levels in adult dopaminergic midbrain neurons result in nigrostriatal degeneration. J Neurosci 2007;27:13997-14006.
14. Solano RM, Casarejos MJ, Menendez-Cuervo J, et al. Glial dysfunction in parkin null mice: effects of aging. J Neurosci 2008; 28:598-611.
15. Haque ME, Asanuma M, Higashi Y, et al. Apoptosis-inducing neurotoxicity of dopamine and its metabolites via reactive quinone generation in neuroblastoma cells. Biochim Biophys Acta 2003;1619:39-52.
16. Miyazaki I, Asanuma M, Diaz-Corrales FJ, et al. Dopamine agonist pergolide prevents levodopa-induced quinoprotein formation in parkinsonian striatum and shows quenching effects on dopamine-semiquinone generated in vitro. Clin Neuropharmacol 2005;28:155-160.
17. Diaz-Corrales FJ, Asanuma M, Miyazaki I, et al. Rotenone induces aggregation of gamma-tubulin protein and subsequent disorganization of the centrosome: relevance to formation of inclusion bodies and neurodegeneration. Neuroscience 2005;133: 117-135.
18. Lee JM, Calkins MJ, Chan K, et al. Identification of the NF-E2-related factor-2-dependent genes conferring protection against oxidative stress in primary cortical astrocytes using oligonucleotide microarray analysis. J Biol Chem 2003;278:12029-12038.
19. Donato R. Intracellular and extracellular roles of S100 proteins. Microsc Res Tech 2003;60:540-551.
20. Selinfreund RH, Barger SW, Pledger WJ, Van Eldik LJ. Neurotrophic protein S100 beta stimulates glial cell proliferation. Proc Natl Acad Sci USA 1991;88:3554-3558.
21. Tokinaga N, Mizono K, Okada M, et al. Effects of antiepileptic drugs on epoxide hydrolase and glutathione-S-transferase activities. Epilepsia 1996;37(suppl 3):101-102.
22. Shih AY, Johnson DA, Wong G, et al. Coordinate regulation of glutathione biosynthesis and release by Nrf2-expressing glia potently protects neurons from oxidative stress. J Neurosci 2003; 23:3394-3406.
23. Asanuma M, Miyazaki I, Ogawa N. Dopamine- or L-dopa-induced neurotoxicity: the role of dopamine quinone formation and tyrosinase in a model of Parkinson's disease. Neurotox Res 2003; 5:165-176.
24. Graham DG. Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinones. Mol Pharmacol 1978;14:633-643.
25. Ogawa N, Asanuma M, Miyazaki I, et al. L-dopa treatment from the viewpoint of neuroprotection: possible mechanism of specific and progressive dopaminergic neuronal death in Parkinson's disease. J Neurol 2005;252(suppl 4):iv23-iv31.
26. Sulzer D, Zecca L. Intraneuronal dopamine-quinone synthesis: a review. Neurotox Res 2000;1:181-195.
27. Sulzer D, Bogulavsky J, Larsen KE, et al. Neuromelanin biosynthesis is driven by excess cytosolic catecholamines not accumulated by synaptic vesicles. Proc Natl Acad Sci USA 2000;97: 11869-11874.
28. Tse DC, McCreery RL, Adams RN. Potential oxidative pathways of brain catecholamines. J Med Chem 1976;19:37-40.
29. Fornstedt B, Rosengren E, Carlsson A. Occurrence and distribution of 5-S-cysteinyl derivatives of dopamine, dopa and dopac in the brains of eight mammalian species. Neuropharmacology 1986;25:451-454.
30. Kuhn DM, Arthur RE Jr, Thomas DM, Elferink LA. Tyrosine hydroxylase is inactivated by catechol-quinones and converted to a redox-cycling quinoprotein: possible relevance to Parkinson's disease. J Neurochem 1999;73:1309-1317.
31. LaVoie MJ, Ostaszewski BL, Weihofen A, et al. Dopamine covalently modifies and functionally inactivates parkin. Nat Med 2005;11:1214-1221.
32. Machida Y, Chiba T, Takayanagi A, et al. Common anti-apoptotic roles of parkin and alpha-synuclein in human dopaminergic cells. Biochem Biophys Res Commun 2005;332:233-240.
33. Whitehead RE, Ferrer JV, Javitch JA, Justice JB. Reaction of oxidized dopamine with endogenous cysteine residues in the human dopamine transporter. J Neurochem 2001;76:1242-1251.
34. Xu Y, Stokes AH, Roskoski R Jr, Vrana KE. Dopamine, in the presence of tyrosinase, covalently modifies and inactivates tyrosine hydroxylase. J Neurosci Res 1998;54:691-697.
35. Ogawa N, Tanaka K, Asanuma M. Bromocriptine markedly suppresses levodopa-induced abnormal increase of dopamine turnover in the parkinsonian striatum. Neurochem Res 2000;25: 755-758.
36. Hastings TG. Enzymatic oxidation of dopamine: the role of prostaglandin H synthase. J Neurochem 1995;64:919-924.
37. Lai CT, Yu PH. Dopamine- and L-β-3,4-dihydroxyphenylalanine hydrochloride (L-dopa)-induced cytotoxicity towards catecholaminergic neuroblastoma SH-SY5Y cells. Effects of oxidative stress and antioxidative factors. Biochem Pharmacol 1997;53: 363-372.
38. Miyazaki I, Asanuma M. Approaches to prevent dopamine quinoneinduced neurotoxicity. Neurochem Res 2009;34:698-706.
39. Fahn S, Oakes D, Shoulson I, et al. Levodopa and the progression of Parkinson's disease. N Engl J Med 2004;351:2498-2508.
40. Sechi G, Deledda MG, Bua G, et al. Reduced intravenous glutathione in the treatment of early Parkinson's disease. Prog Neuropsychopharmacol Biol Psychiatry 1996;20:1159-1170.
41. Hauser RA, Lyons KE, McClain T, et al. Randomized, doubleblind, pilot evaluation of intravenous glutathione in Parkinson's disease. Mov Disord 2009;19:19.
42. Zeevalk GD, Razmpour R, Bernard LP. Glutathione and Parkinson's disease: is this the elephant in the room? Biomed Pharmacother 2008;62:236-249.
43. Masuda Y, Utsui Y, Shiraishi Y, et al. Relationships between plasma concentrations of diphenylhydantoin, phenobarbital, carbamazepine, and 3-sulfamoylmethyl-1,2-benzisoxazole (AD-810), a new anticonvulsant agent, and their anticonvulsant or neurotoxic effects in experimental animals. Epilepsia 1979;20: 623-633.